Skip to main content
. 2018 Nov 30;33(4):473–484. doi: 10.3803/EnM.2018.33.4.473

Table 4. Subgroup Analysis of the Associations between HT and Clinicopathological Features of Papillary Thyroid Cancer by Study Location.

Variable Asia Non-Asia
Total Europe America
No. of studies No. of HT/non-HT OR (95% CI) No. of studies No. of HT/non-HT OR (95% CI) No. of studies No. of HT/non-HT OR (95% CI) No. of tudies No. of HT/non-HT OR (95% CI)
ETE 26 6,266/19,912 0.75 (0.70–0.80) 12 1,045/2,615 0.75 (0.62–0.89) 5 302/1,036 0.74 (0.54–1.02) 7 743/1,579 0.75 (0.51–1.05)
Multifocality 25 6,374/19,289 1.19 (1.05–1.34) 17 1,755/3,681 1.20 (0.95–1.53) 9 953/2,398 1.09 (0.78–1.51) 8 802/1,283 1.36 (0.95–1.95)
LN metastasis 35 7,576/23,949 0.81 (0.71–0.93) 22 2,191/5,429 0.88 (0.62–1.25) 11 1,172/3,613 1.10 (0.59–2.06) 11 1,019/1,816 0.68 (0.50–0.93)
Distant metastasis 3 261/2,173 0.63 (0.19–2.01) 5 696/2,048 0.47 (0.30–0.76) 3 578/1,639 0.53 (0.32–0.87) 2 118/409 0.19 (0.03–1.06)
Recurrence 14 2,365/9,996 0.55 (0.43–0.70) 5 474/995 0.39 (0.27–0.57) 3 350/864 0.37 (0.23–0.59) 2 124/131 0.43 (0.22–0.85)

HT, Hashimoto thyroiditis; OR, odds ratio; CI, confidence interval; ETE, extrathyroidal extension; LN, lymph node.